Webcast ImageWebcast
Q4 2017 Geron Earnings Conference Call (Replay)
Q4 2017 Geron Earnings Conference Call
Monday, March 19, 2018 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.
Recent NewsMore >>
Mar 16, 2018Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent EventsPrinter Friendly Version
Feb 22, 2018Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial ResultsPrinter Friendly Version
Dec 12, 2017Geron Reports Imetelstat Presentations at American Society of Hematology Annual MeetingPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Corporate Presentation
Download Documentation January 2018
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.15 (3.46%)
Data as of Mar 20, 2018 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Contact Information

Anna Krassowska, Ph.D.

 Print Page |  E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts